A/Prof Matthew Foote announced as Icon’s Deputy Director Radiation Oncology

Icon Writers / 28 Apr, 2023

Icon is pleased to announce that A/Prof Matthew Foote has been appointed Deputy Director Radiation Oncology.

A/Prof Foote brings a wealth of experience and clinical expertise to this new leadership role. As an internationally recognised Radiation Oncologist renowned for his treatment of brain, head and neck and skin cancers, A/Prof Foote is at the forefront of innovation in radiation therapy practice.

He currently plays a key role in advancing Icon’s radiation services, including the roll-out of HyperArc and stereotactic radiation therapy. He also maintains a strong public practice and continues to contribute to advancements in radiation therapy for brain cancers across the public sector, particular across South-East Queensland.

Icon Group Chief Medical Officer, Dr Ian Irving says A/Prof Foote’s clinical excellence and dedication to patient care means he is perfectly positioned to lead the continued growth of our radiation oncology offering.

“A/Prof Foote is a highly regarded clinician with a deep dedication to improving patient outcomes through the advancement of radiation therapy treatments,” said Dr Irving.

“His exceptional standing within our profession and his commitment to research and innovation allows us to continue building on our radiation oncology capabilities and continue to place our patients at the centre.”

A/Prof Foote will work alongside Director of Radiation Oncology, Dr Marcel Knesl and maintain his public and private practice.

Icon Group CEO, Mark Middleton said this appointment further cements Icon’s commitment to clinical leadership.

“A/Prof Foote is just one example of our respected clinicians. We have built a truly integrated, stable, and international network of doctors who are dedicated to improving access to cancer care. This clinical leadership, coupled with our robust governance structures, enable us to deliver on our mission and continue to uphold patient safety,” said Mark Middleton.

View our full clinical leadership team here.

View all News


Contact us